At the tissue level, in vitro work using isolated pancreatic islets has characterised tirzepatide's effect on glucose-stimulated insulin secretion (GSIS), with multiple groups reporting that the dual-agonist produces greater cAMP accumulation in -cells than mono-agonists at matched concentrations
In 2024, the Food and Drug Administration approved Wegovy to reduce the risk of serious cardiovascular events in adults with cardiovascular disease and obesity or overweight, alongside diet and physical activity
Habit 5: Prioritize a Protein-rich Breakfast for GLP-1 Protein is the most satiating macronutrient, which is one reason high-protein breakfasts consistently outperform high-carbohydrate breakfasts for hunger control
In trials of the branded formulations, STEP 1 reported a -14.9% mean body-weight change with semaglutide at 68 weeks, and SURMOUNT-1 reported -20.9% with 15 mg tirzepatide at 72 weeks
The potential benefits and risks are based on our understanding of how the medication influences gut motility and digestion